Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Ronald Chen MD MPH
Temporarily Closed to Accrual
March 5, 2020
Most Recent Amendment Date:
September 18, 2020
Primary Objective:Compare metastasis-free survival (MFS) of salvage RT and GnRH agonist/antagonist vs. RT/ GnRH agonist/antagonist with abiraterone acetate with prednisone and apalutamide for patients with pathologic node-positive prostate cancer after radical prostatectomy with detectable PSA.
Compare health-related quality of life (EPIC-26, EQ-5D-5L, Brief Pain Inventory, PROMIS-Fatigue) among the treatment arms.
Compare overall survival, biochemical progression-free survival, time to local-regional progression, time to castrate resistance, and cancer-specific survival among the treatment arms.
Compare the short-term and long-term treatment-related adverse events among the treatment arms.
Pathologic node-positive prostate cancer patients after radical prostatectomy and currently having a detectable PSA.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.